
AACR 2022 – A weekend of updates yields few winners
The dour biotech market sees little to be impressed about in updates from Bicycle, Rubius, C4 and Zentalis, though well-received data gives Affimed a boost.

Esmo 2021 – Astra finally sees a Wee1 signal
It might be too late for adavosertib, but others could benefit if a niche has finally been found for Wee1 inhibitors.

The search for a better Faslodex continues
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.

AACR 2021 preview – the early themes emerge
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.